ONES Stock Overview
Engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Oneness Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$13.60 |
| 52 Week High | NT$0 |
| 52 Week Low | NT$0 |
| Beta | 1.66 |
| 1 Month Change | -16.05% |
| 3 Month Change | -39.29% |
| 1 Year Change | -57.23% |
| 3 Year Change | -73.85% |
| 5 Year Change | n/a |
| Change since IPO | -73.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| ONES | LU Pharmaceuticals | LU Market | |
|---|---|---|---|
| 7D | 3.0% | 0% | 0% |
| 1Y | -57.2% | 0% | 0% |
Return vs Industry: ONES underperformed the Luxembourg Pharmaceuticals industry which returned -1.2% over the past year.
Return vs Market: ONES underperformed the Luxembourg Market which returned -5% over the past year.
Price Volatility
| ONES volatility | |
|---|---|
| ONES Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in LU Market | 0% |
| 10% least volatile stocks in LU Market | 0% |
Stable Share Price: ONES's share price has been volatile over the past 3 months compared to the Luxembourg market.
Volatility Over Time: ONES's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Luxembourg stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Shuling Cheng | www.onenessbio.com |
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials.
Oneness Biotech Co., Ltd. Fundamentals Summary
| ONES fundamental statistics | |
|---|---|
| Market cap | US$1.29b |
| Earnings (TTM) | -US$38.39m |
| Revenue (TTM) | US$3.42m |
377.1x
P/S Ratio-33.6x
P/E RatioIs ONES overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONES income statement (TTM) | |
|---|---|
| Revenue | NT$112.20m |
| Cost of Revenue | NT$49.12m |
| Gross Profit | NT$63.08m |
| Other Expenses | NT$1.32b |
| Earnings | -NT$1.26b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.64 |
| Gross Margin | 56.22% |
| Net Profit Margin | -1,121.83% |
| Debt/Equity Ratio | 0% |
How did ONES perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 13:15 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oneness Biotech Co., Ltd. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Jianzheng Wu | Capital Securities Corporation |
| Regina Lee | Jih Sun Securities Investment Consulting Co., Ltd. |